Prof. Dr. rer. nat. Dr. med. Cornelia Mauch - Curriculum Vitae

Education and professional career

2015: Paul Gerson Unna Medal (awarded by the DFG)
2011: Oncology Award, Stettendorf Foundation
since 2010: Head of Skin Tumour Center, University of Cologne (certified by the DFG)
since 2003: C3-Professor of Dermatology, University of Cologne
1996 - 2002: Assistant Professor of Dermatology, University of Cologne
1997: Faculty Research Award, University of Cologne
1993 - 1996: Residency in Dermatology and Venereology, University of Cologne, Habilitation
1993: MD, Medical Faculty, Ludwig Maximilians University, Munich
1991 - 1993: Postdoctoral fellow of the German Cancer Research Center, Heidelberg
1990: Young Investigator Award, German Society of Cell Biology
1986: PhD, Max-Planck-Institute of Biochemistry, Martinsried
1984 - 1990: Medical training, Ludwig Maximilians University, Munich
1982: Bachelor of Science in Biology and Chemistry, University of Regensburg

Selected publications

Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretic L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell. 2015, 162, 146-159.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372, 320-330.

Reuter K, Albrecht K, Seelig H, Meiss F, Mauch C, Kreuzberg N, Nashan D. Health-related quality of life, fatigue, and depression under low-dose IFN-a therapy in melanoma patients. J Immunother. 2014, 37, 461-467.

Leufke C, Leykauf J, Krunic D, Jauch A, Holtgreve-Grez H, Böhm-Steuer B, Bröcker EB, Mauch C, Utikal J, Hartschuh W, Purdie KJ, Boukamp P. The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas. Oncogene. 2014, 33, 3506-3518.

Augustin I, Gross J, Baumann D, Korn C, Kerr G, Grigoryan T, Mauch C, Birchmeier W, Boutros M. Loss of epidermal Evi/WIs results in a phenotype resembling psoriasiform dermatitis. J Exp Med. 2013, 210, 1761-1777.

Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, Schüll S, Andree M, Coutelle O, Yazdanpanah B, Seeger JM, Klubertz D, Drebber U, Hacker UT, Krönke M, Mauch C, Hoppe T, Kashkar H. Ubiquitin C-terminal hydroxylase-L 1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 2013, 3, 881-891.

Rabenhorst A, Schlaak M, Heukamp LC, Förster A, Theurich S, von Bergwelt-Baildon M, Büttner R, Kurschat P, Mauch C, Roers A, Hartmann K. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012, 120, 2042-2054.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kämpgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Harvey P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet. 2012, 380, 358-365.

Abety AN, Fox JW, Schönefuß A, Zamek J, Landsberg J, Krieg T, Blobel C, Mauch C, Zigrino P. Stromal fibroblast-specific expression of ADAM-9 modulates proliferation and apoptosis in melanoma cells in vitro and in vivo. J Invest Dermatol. 2012, 132, 2451-2458.

Jin G, Zhang F, Chan KM, Xavier Wong HL, Liu B, Cheah KS, Liu X, Mauch C, Liu D, Zhou Z. MT1-MMP cleaves DII1 to negatively regulate Notch signalling to maintain normal B cell development. Embo J. 2011, 30, 2281-2293.

Thierauf J, Veit JA, Affolter A, Bergmann C, Grünow J, Laban S, Lennerz JK, Grünmüller L, Mauch C, Pinkert PK, Hess J, Hoffmann TK (2015). Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res 25(6): 503-509.

Taylor SH, Yeung CY, Kalson NS, Lu Y, Zigrino P, Starborg T, Warwood S, Holmes DF, Canty-Laird EG, Mauch C, Kadler KE (2015). Matrix metalloproteinase 14 is required for fibrous tissue expansion. Elife 2015 Sep. 21: e09345.

Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M (2015). Intermittent high-dose intravenous interferon ???b for adjuvant treatment of stage III melanoma: Final analysis of a randomized phase III dermatologic cooperative oncology group trial. J Clin Oncol 33(34): 4077-4084.

Heuser S, Hufbauer M, Steiger J, Marshall J, Sterner-Kock A, Mauch C, Zigrino P, Akgül B (2016). The fibronectin/?3ß1 integrin axis serves as molecular basis for keratinocyte invasion induced by ßHPV. Oncogene. 2016, Jan 25. doi: 10.1038/onc.2015.512 (Epub ahead of print)y group trial. J Clin Oncol 33(34): 4077-4084.

Zigrino P, Brinckmann J, Niehoff A, Lu Y, Giebeler N, Eckes B, Kadler KE, Mauch C (2016). Fibroblast-derived MMP-14 regulates collagen homeostasis in adult skin. J Invest Dermatol.  2016, Apr 9. doi:10.1016/j.jid.2016.03.036 (Epub ahead of print).

Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, Vogt T, Ulrich J, Herbst R,  Gehring W, Simon JC, Keim U, Martus P, Garbe C; German Dermatologic     Cooperative Oncology Group (DeCOG) (2016). Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicenter, randomised, phase 3 trial. Lancet Oncol 17(6): 757-767.

Zigrino P, Brinckmann J, Niehoff A, Lu Y, Giebeler N, Eckes B, Kadler KE,     Mauch C. Fibroblast-Derived MMP-14 Regulates Collagen Homeostasis in Adult Skin.  J Invest Dermatol. 2016 Aug;136(8):1575-83. doi: 0.1016/j.jid.2016.03.036. Epub 2016 Apr 9.

Giebeler N, Schönefuß A, Landsberg J, Tüting T, Mauch C, Zigrino P. Deletion of  ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.  Oncogene. 2017 May 29. doi: 10.1038/onc.2017.162. [Epub ahead of print].

Mescher M, Jeong P, Knapp SK, Rübsam M, Saynisch M, Kranen M, Landsberg     J, Schlaak M, Mauch C, Tüting T, Niessen CM, Iden S. The epidermal polarity     protein Par3 is a non-cell autonomous suppressor of malignant melanoma. J Exp Med. 2017 Feb;214(2):339-358. doi: .1084/jem.20160596. Epub 2017 Jan 17.